Prior to the initiation or alteration of ART, the clinician should identify any potential barriers and compliance issues. The development of novel drugs and enhanced formulations have led to better medication tolerability, less toxicity, and increased adherence.

Mothers who are HIV positive should be discouraged from breastfeeding neonates who do not have a confirmed HIV positive status. If a female continues to breastfeed, the infant should be monitored and tested every 3 months throughout breastfeeding and post discontinuation of breastfeeding at the interval of 4-6 weeks, 3 months, and at 6 months.